Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773951 | 0.91 | CNR1 (0.45) | CNR1MAPTALDH1A1HTTNPSR1 | |
| SCHEMBL2773495 | 0.89 | LMNA (0.48) | MAPTALDH1A1HTTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2791558 | 0.88 | LMNA (0.47) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL2774112 | 0.88 | LMNA (0.47) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL2774074 | 0.87 | LMNA (0.48) | ALDH1A1HTTMEN1KMT2AGBA1 | |
| SCHEMBL2774607 | 0.87 | CNR1 (0.49) | CNR1MAPTALDH1A1HTTNPSR1 | |
| SCHEMBL2772031 | 0.87 | BRAF (0.47) | MAPTALDH1A1NPSR1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2790300 | 0.86 | BRAF (0.46) | MAPTALDH1A1NPSR1GAASMN1; SMN2 | |
| SCHEMBL2788465 | 0.85 | GBA1 (0.37) | CNR1MAPTALDH1A1HTTNPSR1 | |
| SCHEMBL2788469 | 0.85 | GBA1 (0.37) | CNR1MAPTALDH1A1HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-06-03 | — | — | US | claimed |
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | CDC25A, CDC25B, CDC25C | CNR1 4292/4885MAPT 4555/4885ALDH1A1 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.